56 related articles for article (PubMed ID: 20043129)
1. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
[TBL] [Abstract][Full Text] [Related]
2. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
Zhang N; Liu L; Dumitru CD; Cummings NR; Cukan M; Jiang Y; Li Y; Li F; Mitchell T; Mallem MR; Ou Y; Patel RN; Vo K; Wang H; Burnina I; Choi BK; Huber HE; Stadheim TA; Zha D
MAbs; 2011; 3(3):289-98. PubMed ID: 21487242
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy.
Zhang B; Shi J; Shi X; Xu X; Gao L; Li S; Liu M; Gao M; Jin S; Zhou J; Fan D; Wang F; Ji Z; Bian Z; Song Y; Tian W; Zheng Y; Xu L; Li W
Drug Resist Updat; 2024 May; 74():101068. PubMed ID: 38402670
[TBL] [Abstract][Full Text] [Related]
4. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.
Khoshtinat Nikkhoi S; Yang G; Owji H; Grizotte-Lake M; Cohen RI; Gil Gonzalez L; Massumi M; Hatefi A
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38490714
[TBL] [Abstract][Full Text] [Related]
5. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
[TBL] [Abstract][Full Text] [Related]
6. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action.
Kast F; Schwill M; Stüber JC; Pfundstein S; Nagy-Davidescu G; Rodríguez JMM; Seehusen F; Richter CP; Honegger A; Hartmann KP; Weber TG; Kroener F; Ernst P; Piehler J; Plückthun A
Nat Commun; 2021 Jun; 12(1):3790. PubMed ID: 34145240
[TBL] [Abstract][Full Text] [Related]
7. Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.
Renner C; Stehle I; Lee FT; Hall C; Catimel B; Nice EC; Mountain A; Rigopoulos A; Brechbiel MW; Pfreundschuh M; Scott AM
Cancer Immunol Immunother; 2001 Apr; 50(2):102-8. PubMed ID: 11401024
[TBL] [Abstract][Full Text] [Related]
8. A Cell-Penetrating Peptide Improves Anti-HER2 Single-Chain Variable Fragment Internalization and Antitumor Activity against HER2-Positive Breast Cancer In Vitro and In Vivo.
Li J; Zhou Y; Su Z; Li X; Zhang L; Li S
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542884
[TBL] [Abstract][Full Text] [Related]
9. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with CD64-directed immunotherapy. An overview.
Curnow RT
Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H
Tanaka T; Suzuki H; Ohishi T; Kaneko MK; Kato Y
Cancer Sci; 2024 Jan; 115(1):298-309. PubMed ID: 37942574
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu.
Pullarkat V; Deo Y; Link J; Spears L; Marty V; Curnow R; Groshen S; Gee C; Weber JS
Cancer Immunol Immunother; 1999 Apr; 48(1):9-21. PubMed ID: 10235484
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function.
Yue J; Shao S; Zhou J; Luo W; Xu Y; Zhang Q; Jiang J; Zhu MM
Invest New Drugs; 2024 Feb; 42(1):106-115. PubMed ID: 38198061
[TBL] [Abstract][Full Text] [Related]
14. In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.
Thakur A; Norkina O; Lum LG
Cancer Immunol Immunother; 2011 Dec; 60(12):1707-20. PubMed ID: 21713642
[TBL] [Abstract][Full Text] [Related]
15. Arg9 facilitates the translocation and downstream signal inhibition of an anti-HER2 single chain antibody.
Hu Y; Qiao C; Lv M; Feng J; Yu M; Shen B; Zhang Q; Li Y
BMC Res Notes; 2012 Jul; 5():336. PubMed ID: 22748113
[TBL] [Abstract][Full Text] [Related]
16. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins.
Weiner LM; Alpaugh RK; von Mehren M
Cancer Immunol Immunother; 1997; 45(3-4):190-2. PubMed ID: 9435871
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
van Ojik HH; Repp R; Groenewegen G; Valerius T; van de Winkel JG
Cancer Immunol Immunother; 1997; 45(3-4):207-9. PubMed ID: 9435875
[No Abstract] [Full Text] [Related]
18. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
DiPeri TP; Evans KW; Wang B; Zhao M; Akcakanat A; Raso MG; Rizvi YQ; Zheng X; Korkut A; Varadarajan K; Uzunparmak B; Dumbrava EE; Pant S; Ajani JA; Pohlmann PR; Jensen VB; Javle M; Rodon J; Meric-Bernstam F
Cancer Discov; 2024 May; 14(5):828-845. PubMed ID: 38358339
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor cell destruction with CD64-directed bispecific fusion proteins.
Graziano RF; Goldstein J; Sundarapandiyan K; Somasundaram C; Keler T; Deo YM
Cancer Immunol Immunother; 1997; 45(3-4):124-7. PubMed ID: 9435854
[No Abstract] [Full Text] [Related]
20. Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity.
Kawaguchi K; Suzuki E; Nishie M; Kii I; Kataoka TR; Hirata M; Inoue M; Pu F; Iwaisako K; Tsuda M; Yamaguchi A; Haga H; Hagiwara M; Toi M
Cancer Immunol Immunother; 2017 Sep; 66(9):1131-1142. PubMed ID: 28432397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
